Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis
about
Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patientsPrecision medicine for HIV: where are we?
P2860
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Lopinavir/ritonavir pharmacoki ...... ents with or without cirrhosis
@en
type
label
Lopinavir/ritonavir pharmacoki ...... ents with or without cirrhosis
@en
prefLabel
Lopinavir/ritonavir pharmacoki ...... ents with or without cirrhosis
@en
P2093
P2860
P1476
Lopinavir/ritonavir pharmacoki ...... ents with or without cirrhosis
@en
P2093
Antonietta Cargnel
David J Back
Giovanna Orlando
Giuliano Rizzardini
Laura Cordier
Laura Dickinson
Maria Cusato
Mario Regazzi
Paola Meraviglia
Paola Villani
P2860
P304
P356
10.1097/FTD.0B013E318177209E
P577
2008-06-01T00:00:00Z